Evidence map›Paper›PMID 40724970›Full record

ArticleInternational journal of molecular sciences2025

Circulating Tumour DNA Is a Biomarker of Response in Angioimmunoblastic T-Cell Lymphoma.

Costas Kleanthes Yannakou, Simon Wu, Karthik Rajah, Chathuri Abeyakoon, Caitlyn Nguyen-Ngo, Yan Zhuang Yap, James Sheldon, Piers Blombery, Henry Miles Prince

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Costas Kleanthes YannakouEpworth HealthCare, Melbourne 3002, Australia.ORCID 0000-0001-6657-2034
Simon WuSir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne 3010, Australia.ORCID 0000-0002-8339-7343
Karthik RajahQML Pathology, Brisbane 4172, Australia.
Chathuri AbeyakoonEpworth HealthCare, Melbourne 3002, Australia.ORCID 0000-0002-8848-9423
Caitlyn Nguyen-NgoEpworth HealthCare, Melbourne 3002, Australia.
Yan Zhuang YapPeter MacCallum Cancer Centre, Melbourne 3000, Australia.
James SheldonEpworth HealthCare, Melbourne 3002, Australia.
Piers BlomberySir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne 3010, Australia.
Henry Miles PrinceEpworth HealthCare, Melbourne 3002, Australia.ORCID 0000-0002-0058-2448

Funding

The Epworth Foundation Not applicableThe Snowdome Foundation Not applicable
6 · The paper itself

Abstract

Angioimmunoblastic T-cell lymphoma (AITL) is a rare and aggressive subtype of non-Hodgkin lymphoma, the monitoring of which is largely restricted to radiological methods. Diagnosis relies on identifying characteristic clinicopathological features, supported by the detection of recurrent somatic mutations in

Indexed as

Biomarkers, TumorCirculating Tumor DNAImmunoblastic LymphadenopathyLymphoma, T-CellAdultAgedAged, 80 and overDioxygenasesDNA-Binding ProteinsDNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3AFemaleHumansIsocitrate DehydrogenaseMaleMiddle AgedBiomarkers, TumorCirculating Tumor DNADioxygenasesDNA-Binding ProteinsDNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3ADNMT3A protein, humanIDH2 protein, humanIsocitrate DehydrogenaseProto-Oncogene ProteinsrhoA GTP-Binding ProteinRHOA protein, humanTET2 protein, humanangioimmunoblastic T-cell lymphomacirculating tumour DNAmeasurable residual disease

Identifiers

PMID40724970
PMCPMC12294795

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.